These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Complications of intravitreal steroid injections. Reichle ML Optometry; 2005 Aug; 76(8):450-60. PubMed ID: 16150412 [TBL] [Abstract][Full Text] [Related]
24. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Ding X; Li J; Hu X; Yu S; Pan J; Tang S Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319 [TBL] [Abstract][Full Text] [Related]
25. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Jain N; Stinnett SS; Jaffe GJ Ophthalmology; 2012 Jan; 119(1):132-7. PubMed ID: 21924503 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of the Intravitreal Sustained-Release Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-Vascular Endothelial Growth Factor Therapy: Meta-Analysis and Clinical Implications. Khan Z; Kuriakose RK; Khan M; Chin EK; Almeida DR Ophthalmic Surg Lasers Imaging Retina; 2017 Feb; 48(2):160-166. PubMed ID: 28195619 [TBL] [Abstract][Full Text] [Related]
27. Corticosteroid Treatment in Diabetic Macular Edema. Nurözler Tabakcı B; Ünlü N Turk J Ophthalmol; 2017 Jun; 47(3):156-160. PubMed ID: 28630791 [TBL] [Abstract][Full Text] [Related]
28. Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system. Augustin AJ Expert Opin Drug Deliv; 2011 Feb; 8(2):271-9. PubMed ID: 21222552 [TBL] [Abstract][Full Text] [Related]
33. Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease. Comyn O; Lightman SL; Hykin PG Curr Opin Ophthalmol; 2013 May; 24(3):248-54. PubMed ID: 23518614 [TBL] [Abstract][Full Text] [Related]
34. Delivery of steroids into the eye for the treatment of macular edema. Hadayer A; Schaal S Expert Opin Drug Deliv; 2016 Aug; 13(8):1083-91. PubMed ID: 27105838 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological approach to diabetic macular edema. Bandello F; Casalino G; Loewenstein A; Goldstein M; Pelayes D; Battaglia Parodi M Ophthalmic Res; 2014; 51(2):88-95. PubMed ID: 24356667 [TBL] [Abstract][Full Text] [Related]
36. Intravitreal therapeutic agents in noninfectious uveitic macular edema. Shah KK; Majumder PD; Biswas J Indian J Ophthalmol; 2018 Aug; 66(8):1060-1073. PubMed ID: 30038143 [TBL] [Abstract][Full Text] [Related]
37. An update on intravitreal implants in use for eye disorders. Lambiase A; Abdolrahimzadeh S; Recupero SM Drugs Today (Barc); 2014 Mar; 50(3):239-49. PubMed ID: 24696869 [TBL] [Abstract][Full Text] [Related]
38. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Elbendary AM; Shahin MM Retina; 2011 Nov; 31(10):2058-64. PubMed ID: 21765371 [TBL] [Abstract][Full Text] [Related]
39. PROSPECTIVE EVALUATION OF A SUSTAINED-RELEASE DEXAMETHASONE INTRAVITREAL IMPLANT FOR CYSTOID MACULAR EDEMA IN QUIESCENT UVEITIS. Khurana RN; Bansal AS; Chang LK; Palmer JD; Wu C; Wieland MR Retina; 2017 Sep; 37(9):1692-1699. PubMed ID: 27893624 [TBL] [Abstract][Full Text] [Related]
40. Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Goff MJ; Jumper JM; Yang SS; Fu AD; Johnson RN; McDonald HR; Ai E Retina; 2006 Oct; 26(8):896-901. PubMed ID: 17031289 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]